Bernhardt Marit, Kristiansen Glen
Institute of Pathology, University Hospital Bonn, 53127 Bonn, Germany.
Cancers (Basel). 2023 Nov 22;15(23):5512. doi: 10.3390/cancers15235512.
Intraductal carcinoma of the prostate is most commonly associated with high-grade invasive prostate cancer. However, isolated IDC-P without adjacent cancer or high-grade cancer is also well known. Common genetic alterations present in IDC-P with adjacent high-grade prostate cancer are those described in high-grade tumors, such as PTEN loss (69-84%). In addition, the rate of LOH involving and is significantly higher. IDC-P is common in the TCGA molecular subset of mutant cancers, and the presence of mutations are more likely in IDC-P bearing tumors. IDC-P without adjacent high-grade cancers are by far less common. They are less likely to have PTEN loss (47%) and rarely harbor an ERG fusion (7%). Molecular alterations that may predispose a person to the development of IDC-P include the loss of and as well as mutations in . However, the causative nature of these genetic alterations is yet to be validated.
前列腺导管内癌最常与高级别浸润性前列腺癌相关。然而,孤立的无相邻癌或高级别癌的前列腺导管内癌(IDC-P)也广为人知。与相邻高级别前列腺癌相关的IDC-P中常见的基因改变是那些在高级别肿瘤中描述的改变,如PTEN缺失(69%-84%)。此外,涉及[具体基因]和[具体基因]的杂合性缺失率明显更高。IDC-P在[特定基因]突变癌症的TCGA分子亚组中很常见,并且在携带IDC-P的肿瘤中[特定基因]突变的可能性更大。无相邻高级别癌的IDC-P极为少见。它们发生PTEN缺失的可能性较小(47%),且很少有ERG融合(7%)。可能使人易患IDC-P的分子改变包括[具体基因]和[具体基因]的缺失以及[具体基因]的突变。然而,这些基因改变的因果性质尚未得到证实。